PF-07220060

Phase 2Small molecule

Pfizer

PF-07220060 is one of 77 small molecule programs targeting Liposarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LiposarcomaRecruiting

Breast CancerCompleted

ESSRecruiting

LiposarcomaPhase 2

Recruiting

Breast CancerPhase 2

Completed

ESSPhase 1

Recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

PF-07220060

Pfizer

Phase 2

5 2

Lexiscan

Astellas

Preclinical

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 4

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Ablavar

LLantheus Medical Imaging

Preclinical

2 7

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 8

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 9

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 10

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Breast Cancer

NCT05262400

Q2 2027

Phase 1Recruiting

Breast Cancer

NCT05216432

PreclinicalActive, not recruiting

Breast Cancer

NCT06206837

Q1 2028

Phase 2Active, not recruiting

Advanced or Metastatic Breast Cancer

NCT06105632

Q3 2029

Phase 2Recruiting

Breast Carcinoma

NCT04606446

Clinical

Trials by Indication[1]

Breast Cancer5 trials

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Recruiting· Relay Therapeutics logo

Relay Therapeutics·Phase 1·NCT05216432·930 enrolled

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT06760637·1,035 enrolled

AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH PF-07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ER+/HER2- ADVANCED OR METASTATIC BREAST CANCER

Active, not recruiting· Pfizer logo

Pfizer·Preclinical·NCT06206837·71 enrolled

Show 2 more trials

A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Active, not recruiting· Pfizer logo

Pfizer·Preclinical·NCT05262400·235 enrolled

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO LETROZOLE ALONE IN POSTMENOPAUSAL WOMEN 18 YEARS OR OLDER WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER IN THE NEOADJUVANT SETTING

Completed· Pfizer logo

Pfizer·Phase 2·NCT06465368·121 enrolled

ART1 trial

A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT07130097·35 enrolled

CAR1 trial

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

Completed· Pfizer logo

Pfizer·Phase 1·NCT06897683·14 enrolled

ESS1 trial

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07160738·28 enrolled

Adult1 trial

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT06267963·12 enrolled

3 more indications

Liposarcoma1 trial

A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Recruiting·BBlueprint Medicines·Preclinical·NCT04557449·430 enrolled

Breast Carcinoma1 trial

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Recruiting· Pfizer logo

Pfizer·Phase 2·NCT04606446·320 enrolled

Advanced or Metastatic Breast Cancer1 trial

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT06105632·333 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for PF-07220060. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-07220060 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-07220060. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

PF-07220060

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q1 2028

Q3 2029

Trials by Indication[1]

Breast Cancer5 trials

ART1 trial

CAR1 trial

ESS1 trial

Adult1 trial

Liposarcoma1 trial

Breast Carcinoma1 trial

Advanced or Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News